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One-quarter of a century ago, identification of the human retino-
blastoma gene (RB) loci proved Knudson’s ‘two-hit theory’ that
tumor suppressor genes exist. Since then, numerous works delin-
eated crucial roles for the RB protein (pRB)-E2F transcription factor
complex in G1-S phase transition. In addition, discovering the rela-
tionship between pRB and tissue-specific transcription factors
enabled a better understanding of how cell cycle exit and terminal
differentiation are coupled. Recent works provoked many exciting
twists in views on pRB functions during cancer initiation and pro-
gression beyond its previously well-appreciated roles. Various
mitogenic and cytostatic cellular signals appeared to modulate
pRB functions and thus affect a wide variety of effector molecules.
In addition, genetic studies in mice as well as other creatures
incessantly force us to revise our views on pRB functions. This
review will focus particularly on the roles of pRB in regulating
intracellular signaling, cell metabolism, chromatin function, stem
cells and cancer stem cells. (Cancer Sci 2012; 103: 1182–1188)
R B mutation is found prevalently in retinoblastomas, osteo-sarcomas and small-cell lung carcinomas, and such a spec-
trum of tumors is reproducible in Rb-deficient mice.(1) These
findings suggest that in these tumors RB mutation occurs when
tumors initiate. However, in the majority of cancers, including
prostate, breast, bladder, esophageal, hepatic cancers, glioma or
chronic myelogenous leukemia, inactivation of pRB functions
caused by either mutation, gene deletion, promoter methylation,
deregulated phosphorylation or decreased protein level usually
occurs during cancer progression.(2) Some evidence proposes
that pRB is even ‘required’ for tumor initiation in these cancers
due to its anti-apoptotic function or cooperation with Ras-trans-
formation.(3,4) Despite having redundant functions for control-
ling G1-S transition, other ‘pocket protein’ family members
p107 and p130 are rarely mutated in cancers. These findings, as
well as other discoveries (discussed later), suggest that pRB
might possess many more multifaceted and unique functions
than previously thought. Compared with its smaller protein
abundance (in empirical terms), pRB appears to possess ‘too
many’ functions, and some of them cause both positive and
negative effects on the same biological event. This implies that
a particular pRB function (or an effect of pRB inactivation) is
selected depending on the cellular context or cancer stage.
Upstream Signals and Downstream Effectors of pRB
Various mitogenic signals (e.g. receptor tyrosine kinases/Ras,
Akt, NF-jB, Shh, Hippo, Wnt, Myc, Jak/STAT) merge more or
less on the upregulation of D-type cyclins, initiating pRB
phosphorylation executed sequentially by cyclin D-CDK4/6 and
cyclin E-CDK2. This prevents pRB from suppressing E2F
function to transactivate the targeted genes. In addition, in
response to DNA damage, ATM and Chk1/2 directly phosphory-
late pRB.(5) AMP-activated kinase (AMPK) also directly phos-
phorylates pRB; this contributes to energy control favoring
neural progenitor cell growth.(6) Furthermore, pRb phosphoryla-
tion induced by AMPK leads to E2F1-dependent cell death that
occurs in inner ear cells when they sense mitochondrial defect
(discussed later).(7) Oxidative stress resets pRB phosphorylation
via protein phosphatase 2A (PP2A).(8) As is well documented,
the CDK inhibitors (CDKI) suppress pRB phosphorylation from
genetic upstream by attenuating the catalytic activity of cyclin-
CDK. However, the clinical outcome of CDKI inactivation is not
always equivalent to that of pRB inactivation.(9) pRB inactivation
upregulates p16Ink4a by elevating Ras activity and its tumor sup-
pressor role is taken over by p130.(10) This, as well as previously
described findings,(9) indicate that the genetic interaction
between CDKI and pRB is not linear. Furthermore, in addition to
phosphorylation, many other types of post-translational modifi-
cation regulate pRB activity. For instance, pRB is acetylated by
p300/CBP, PCAF and Tip60, deacetylated by Sirtuin1 (SIRT1),
and methylated by Set7/9 and SMYD.(2,11) These modifications
may alter the susceptibility of pRB to undergo CDK-dependent
phosphorylation or its binding affinity to other partners. Further-
more, pRB is sumoylated and is also catabolized following
MDM2-mediated ubiquitination or caspase 3 and 8-mediated
cleavage at the C-terminus (Fig. 1).(12–14) Mouse models demon-
strated that E2F are crucial downstream mediators of the tumor
suppressor function of pRB. The continuous advancement in our
understanding of the E2F functions increases the number of pos-
sible functions that pRB might possess (discussed later). How-
ever, some mutant forms of pRB are defective in E2F binding
and transcriptional repression, although the proteins partially
retain their tumor suppressor activity.(15) This fact led researchers
to focus on different downstream effectors. pRB directly binds to
Skp2, which allows APC-Cdh1 to ubiquitinate Skp2. Thereby RB
loss allows SCFSkp2 E3 ligase complex to bind to and then ubiq-
uitinate phosphorylated p27Kip1. This nexus appears to be crucial
in carcinogenesis since Rb+/;Skp2/ mice are completely free
of tumor.(16) In addition, EID1 and KDM5A/Jarid1a/RBP2 are
recognized as molecules likely to be involved in E2F-indepen-
dent functions of pRB (discussed later).(17–19) The pRB family
can interact with many enzymes that remodel histones to gener-
ate repressive chromatin (Fig. 1 and discussed later).(20)
Function of pRB in Intracellular Signaling
Ras signal. Ras activity fluctuates in a cell cycle-dependent
manner.(21) Epistasis studies in Caenorhabditis elegans
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proposed that class B synMuv genes including Rb (lin-35) can
control Ras (let-60)-mediated vulval development even from
genetic upstream.(22) Indeed, SV40 large T antigen-mediated
pRb inactivation or loss of Rb induced elevated Ras activity in
mammalian cells.(23,24) The genetic interaction of Rb and Ras
has been analyzed extensively in mouse embryos simulta-
neously lacking Rb and one of the ras isoforms.(25) N- or K-ras
deletion significantly prolonged the life span of Rb-null
embryos. Their differentiation defects in different organs
including muscle cells and erythrocytes were significantly
rescued; however, aberrant cell proliferation and cell death
persisted (results for erythrocytes are unpublished).(26,27) N- or
K-ras deletion in Rb-deficient pituitary tumorigenesis attenu-
ated tumor invasion with concomitant increase in differentia-
tion degree without affecting tumor incidence.(27,28) These
findings implicate that in addition to the previously appreciated
pathway in which Ras is upstream of RB, Ras functions also
downstream of RB in differentiation control and tumor progres-
sion (Fig. 2). Contrary to pituitary, N-ras deletion converts Rb-
deficient calcitonin-producing cell (C cell) adenoma or low
grade adenocarcinoma to highly metastatic adenocarcinoma.(28)
The mechanism of this twist was explained in our later study(10)
as follows: Rb-deficient C cell adenoma cells are sensitive to
DNA damage response induced by mildly elevated N-Ras
activity (at most 10-fold elevation in activity compared with
that of Rb-positive cells, whereas Ras with oncogenic mutation
exhibits an approximately 60-fold increase in activity). Subse-
quently, Rb-deficient C cells undergo ‘paradoxical’ cellular
senescence with the aid of p16Ink4a and p130, which protects
them from further malignant progression.(10) Consistent with
this explanation, Rb-heterozygous mice simultaneously lacking
any of the Ink4a, Arf or Suv39h1 (senescence-inducing genes)
alleles directly developed highly malignant C cell tumors and
at an earlier age (Fig. 3).(10) This provided a further explana-
tion why RB mutation is a relatively infrequent event during
tumor initiation; RB loss-induced carcinogenesis can be antago-
nized by cellular senescence in some types of cells. In a pro-
genitor for human retinoblastoma, RB loss-induced carcinogenesis
might be antagonized by p53-dependent apoptosis.(29) However,
retinoblastoma progression could be antagonized also by
Fig. 1. Modulators and effectors of RB protein (pRB) functions. DNA damage induces phosphorylation of pRB by ATM and Chk1/2, whereas oxi-
dative stress induces dephosphorylation of pRB through PP2A. AMP-activated kinase (AMPK) also phosphorylates pRB. pRB is acetylated by p300,
PCAF, methylated by Set 7/9 and SMYD, and degradaded via MDM2-mediated ubiquitination and caspase 3 and 8 activation. Several molecules,
Skp2, KDM5A and EID1, are activated after dissociation from pRB in an E2F-independent manner. Released Skp2 promotes ubiquitination and
degradation of phospho-p27kip1.
Fig. 2. The genetic interaction between Ras and RB. The Ras signal
induces RB protein (pRB) phosphorylation by upregulating cyclin D1;
this constitutes one of primary mechanisms by which mitogenic signals
control the cell cycle. Inversely, RB status can influence Ras activation
status by regulating sterol regulatory element-binding protein (SREBP)
and isoprenylation-related genes. Thereby, Ras mediates pRB function
to control the indicated biological events.
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senescence since human RB-null retinomas express elevated
p16INK4a and p130 expression, and lose such marks during pro-
gression presumably due to chromosomal instability (CIN) (dis-
cussed later).(30) To determine the mechanism that enables pRB
to cease Ras activation status, pRb transcriptional targets were
determined in Rb-deficient N-ras/ mouse C cell tumor cells
in which proliferation was not affected by the presence of pRb.
This enabled the cell cycle-independent function of pRB to be
determined. The study(10) detected many genes involved in pro-
tein farnesylation and geranylgeranylation (isoprenylation);
these post-translational modifications are essential for Ras to be
matured and activated. In addition, the study discovered that
these genes are dually innervated by E2F and sterol regulatory
element-binding protein (SREBP) transcription factors. The
SREBP are also regulated by E2F (Fig. 4). Consistently, the
same study demonstrated that the enhancement of pRb activity
delays the trafficking of cytosolic N-Ras to Golgi for which
isoprenylation is essential.(10) In addition to N-Ras, many other
small GTPases, CENP-E and CENP-F those with CAAX motifs
are possibly regulated by pRB (Fig. 4). We also observed RhoA
activity was actually suppressed by pRB.(28)
Other signals. A study by another group has demonstrated
that AKTSer473 phosphorylation is specifically upregulated in
cells lacking all RB family members.(31) Although the exact
mechanism is still unclear, our own preliminary study demon-
strated that the kinetics in which acute pRb inactivation acti-
vates AKT seems to be different from that in which pRb
inactivation increases GTP-loaded Ras (Shunsuke Kitajima,
unpublished data, 2011). In addition, elevated Ras activity
reportedly prefers to induce phosphorylation at AKTSer308 rather
than AKTSer473 via the PI3K pathway. Thus, mTORC2 function
as well as Ras should be analyzed to discover more on this
interaction. Of note, RB and TSC2 (downstream of PI3K/AKT
signal) are in a synthetic lethal relationship.(32) The genetic
interaction between RB and PI3K/AKT/mTOR signal has just
begun to be understood. Myc transcription factors are perhaps
one of the most well-recognized pRB transcriptional targets.
N-myc gene amplifications are found in retinoblastoma cases
free from RB mutation, suggesting that Myc functions might be
considerably overlapped with the signals induced by pRB inac-
tivation.(33) In addition, pRB might modulate intracellular sig-
naling by regulating extracellular signaling molecules including
VEGF, FGFR, bFGF, matrix metalloproteinases, interleukin-8,
hypoxia-responsive gene products and Cox-2; the mechanisms
might involve E2F, Id2, Oct-1, HIF-1 or others.(34,35)
Function of pRB in Cell Metabolism
Metabolic pathways. The aforementioned genetic interaction
between RB and Ras mined a new genetic interaction between
RB and SREBP; this further allocated a new role to pRB in
lipid metabolism, since SREBP are master regulators of lipo-
genic and steroidogenic genes.(10,36) Indeed, in our initial
study, pRb appeared to target many of the genes coding
enzymes that participate in fatty acid and cholesterol biosyn-
thesis. In their promoter, these genes possess either sterol regu-
latory elements (SRE) or E2F-binding consensus sequences
or both (Fig. 4).(10) Recently, a new regulator of SREBP has
emerged. Mutated p53 directly binds to SREBP-2 and
enhances its transactivation potential, thus contributing to the
invasive morphology of breast cancer cells in 3D culture prob-
ably due to enhanced geranylgeranylation.(37) SREBP transacti-
vate most genes implicated in the mevalonate (MVA) pathway
that governs farnesylation, geranylgeranylation and cholesterol
synthesis (Fig. 4). This report, in addition to our own study,
tightly linked two important tumor suppressors, pRB and p53,
to the MVA pathway. Another regulator of SREBP is the
PI3K/AKT signaling pathway. An activated AKT signal regu-
lates the SCAP-mediated processing of SREBP precursors, and
also attenuates ubiquitination of mature (nuclear) SREBP by
inhibiting GSK3 function to phosphorylate mature SREBP.(38)
A recent study demonstrated that Lipin1, which is a substrate
for mTORC1 kinase activity, eliminates mature SREBP from
the nucleus.(39) Lipin1 could also link SREBP and p53.(40) One
of the SREBP targets, fatty acid synthase (FASN), has also
been identified to be a pRB transcriptional target.(10) This
product uses NADPH provided by the shunt from the glyco-
lytic pathway (pentose phosphate pathway) and fuels carbon
sources into the MVA pathway. An elevated FASN level dur-
ing tumor progression might well explain the ‘lipidogenic phe-
notype’ in cancer cells.(41) This in conjugation with ‘aerobic
glycolysis (Warburg’s effect)’ constitutes two major metabolic
perturbations featured in cancer cells. Current understanding is
that these mechanisms synergize to efficiently produce and uti-
lize NADPH for the synthesis of macromolecules including
lipids and nucleotides. This occurs while avoiding ROS-pro-
ducing oxidative phosphorylation (OXPHOS) in mitochondria
and preventing ATP production (Fig. 5).(42) In addition,
increased cellular cholesterol might suppress OXPHOS by
altering the components of the mitochondria membrane.(42)
NADPH is also required for the synthesis of glutathione, an
Fig. 3. RB loss-induced carcinogenesis is antagonized by cellular
defense mechanisms such as DNA damage response or cellular senes-
cence controlled by the indicated genes or events, depending on the
cellular context.
Fig. 4. Various oncogenic signals merged on sterol regulatory ele-
ment-binding protein (SREBP) regulations (transcription, processing,
nuclear localization, ubiquitination and transactivation). Because
SREBP genes are dually regulated by E2F and SREBP, pRB gives rise to
a different impact on genes involved in the mevalonate (MVA) path-
way.
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antioxidant. It is of note that wild-type p53 controls glycolysis
in a bipolar manner, for example, by upregulating hexokinase
2, which promotes glycolysis, and TIGAR, which suppresses
glycolysis. In total, inactivation of the p53 function is thought
to result in the shift of cell metabolism to glycolytic (Fig. 5).
Not only sequential regulation of SREBP expression and matu-
ration, but also an astonishing level of cooperation in regulat-
ing cancer cell metabolism is becoming evident between pRB
and p53 (Fig. 5). AMPKa2 was identified to be in a PI3K-sen-
sitive gene group among E2F targets.(43) This molecule func-
tions as a subunit of a system that senses the cellular level of
AMP and antagonizes many metabolic perturbations in cancer
cells mostly driven by mTORC1, TSC2 or SREBP. Therefore,
together with the phopshorylation of pRB by AMPK, these
findings suggest a mutually suppressive genetic interaction
between pRB and AMPK.(6,7) AMPK also functions down-
stream of another tumor suppressor, LKB1.(44) Metformin, an
AMPK agonist, was suggested to lower the cancer risk in indi-
viduals who were administered the drug.(45) Although
E2F-AMPK genetic interaction was initially perceived in the
context of apoptosis control, together with our knowledge on
pRB genetic interaction with SREBP, Ras, AKT, Myc, p53,
Oct-1 and HIF-1, this discovery will further our understanding
of pRB functions in cancer cell metabolism.
Mitochondrial function. pRB controls mitochondrial biogene-
sis and function in dissimilar ways. For instance, pRB sustains
mitochondrial biogenesis under particular stress conditions. Rb
loss induces differentiation defects in cell cycle-exiting erythro-
cytes and myotube-forming muscle cells presumably by reduc-
ing the mitochondrial copy number.(46,47) The latter defect was
associated with features of autophagy/mitophagy, and rescued
by shifting cells to glycolytic status. This further prompted us to
hypothesize that without glycolytic shift, pRB inactivation
might induce a shortage of energy to support ATP-consuming
differentiation processes (i.e. hemoglobin or myogenic protein
synthesis) or even tumor growth. The mechanism linking pRB
inactivation to mitophagy might involve a genetic interaction
between E2F and Bnip3.(48) pRB also controls transcription of
genes involved in mitochondrial functions. This also could
overlap with the mechanism by which pRB controls mitochon-
drial biogenesis. pRB, probably through its functional interac-
tion with KDM5A, is likely to upregulate a number of genes
encoding mitochondrial proteins in human monocytic cells.(49)
Another study conducted in erythrocytes suggested that pRB
affects mitochondrial biogenesis through regulating NRF1,
NRF2a, PPARc or PGC-1b in a slightly more complicated man-
ner.(46) A recent twist in this field is that the pRB-E2F-1 com-
plex appeared to suppress genes implicated in OXPHOS.(50)
Currently, bifurcated roles of pRB in controlling mitochondrial
biogenesis and OXPHOS are unexplained, but this is an intrigu-
ing conundrum to solve (Fig. 5). In addition, pRB seems to par-
ticipate in the regulation of cellular reactive oxygen species
(ROS) levels, and undergoes feedback from ROS through
CDKI, PP2A, SIRT1 or seladin.(51) Various metabolic pathways
controlled by pRB might counterbalance each other in order to
keep homeostatic control of cellular metabolism.
Function of pRB in Chromatin Functions
CIN and DNA damage. Increased CIN is one of the represen-
tative events seen during progression of cancers. pRB inactiva-
tion undermines genome stability through various mechanisms
that are E2F dependent (e.g. via Mad2, cyclin E-driven hyper-
replication, nucleotide deficiency) or independent (e.g. via
pRB complex with cohesin and condensin II).(52,53) As dis-
cussed above, CIN can contribute to retinoblastoma progres-
sion. Mad2-induced CIN provides causality to not only
tumorigenesis but also to tumor relapse.(54) In addition to such
mechanisms, pRB inactivation can induce DNA damage
response and senescence due to mildly elevated Ras activ-
ity.(10) Because of such diverged roles of pRB in genome sta-
bility, the nature of signals generated by the DNA damage
response induced by pRB inactivation would be different from
those induced by other stimuli, for example, oncogenic Ras or
Raf. We are currently investigating how pRb status modulates
the DNA damage response driven by ATM.
Epigenetic control. A recent study(55) reported that epigenetic
changes rather than CIN induced by RB loss contributes more
strongly to retinoblastoma development. Among the genes that
are epigenetically regulated by pRB, spleen tyrosine kinase
(SYK) appears to play the most critical role.(55) The exact role
and mechanism of pRB in epigenetic control is still unclear.
Many chromatin modifiers with the LxCxE motif, including
DNMT1 (DNA methyltransferase), Suv39H1, Suv4-20H1
(methyltransferase), HP1 (histone H3me3-binding protein),
Brm1, BRG1 (ATP-dependent helicases) and HDAC (histone
deacetylases), and many of the histone demethylases, including
KDM5A, bind to pRB.(20) In addition, new insights on the
‘metabolic reprogramming’ caused in part by pRB and p53
double inactivation has led us to investigate its indirect but
noteworthy impact on the chemical modification of chromatin-
modifying enzymes by altering the cellular levels of metabo-
lites such as nicotinamide adenine dinucleotide+ (NAD+),
flavin adenine dinucleotide (FAD) or a-ketoglutarate.
Function of pRB in Cell Fate Decision
The role of pRB in terminal differentiation has been well doc-
umented by its ability of binding to or functioning with line-
age-specific transcription factors including MyoD, C/EBPa,
GRa, GATA-1, PU1, CBFA-1, Pdx1, Runx2 and NF-Il6. In
addition, pRB suppresses Id2, KDM5A and EID1, which dis-
turb differentiation. pRB has a crucial role in cell fate deci-
sion. For instance, pRB status determines whether p53-mutated
osteosarcoma cells accept osteogenic or fat fate.(56) This used
to be explained by the functional interaction of pRB with
Fig. 5. Various oncogenic signals contribute to metabolic perturba-
tion in cancer cells. Simultaneous inactivation of RB protein (pRB) and
p53 might optimize coupling of glycolytic and lipidogenic phenotypes,
which is facilitated by NADPH production through the pentose phos-
phate pathway (PPP). Red arrows indicate the flow of carbon sources
(CS).
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RUNX2 and PPARc. Nevertheless, the impact of ‘metabolic
reprogramming’ on the differentiation program that stems from
the synergistic p53 and pRB inactivation is also a possible
explanation. Furthermore, the pRB-p53 alliance appears to
determine tumor subtypes through an unknown mechanism.
The destruction of this mutually aiding partnership appears to
shift breast and lung cancers to more primitive or epithelial-
mesenchymal transition (EMT)-like types.(57,58)
Function of pRB in Stem Cells and Cancer Stem Cells
Tissue stem cells. The intrinsic role of pRB in tissue stem
cells has long been debated because studies on the extrinsic
role of pRB in hematopoietic stem cells (HSC) for fetal–mater-
nal nutrient exchange through placenta or bone marrow niche
–hematopoietic stem cell adhesion had previously had a pre-
vailing impact on the field.(59,60) However, recently the intrin-
sic role of pRB in HSC for oxidative stress response or
mitochondrial biogenesis is also appreciated.(46,51) A surprising
twist came from plant studies. Arabidopsis thaliana lacking a
RB ortholog showed expansion in the root stem cell pool with-
out losing its self-renewal capacity; this again stimulated a
debate on the role of pRB in stem cells.(61,62)
Embryonic stem cells. Embryonic stem (ES) cell biology and
induced pluripotent stem (iPS) cell technology indicated a
requirement of carcinogenic signals for the induction of gen-
ome-wide chromatin remodeling and ‘stemness’. Compared
with adult somatic cells, ES or iPS cells exhibit an extraordi-
narily short G1 phase. The length of G1 could be one of the
determinants of the fate of ES cells of whether to stay in a
pluripotent state or to differentiate.(63) A short G1 is at least in
part due to pRB hyperphosphorylation and suppression of p53
transcription.(64) Nanog seems to maintain pRB at the hyper-
phosphorylated status via CDK6 or CDC25A. (65) In contrast,
loss of p53 promoted the efficacy of iPS cell induction.(66) The
p53-mSin3a-HDAC transcription suppressive complex present
on the Nanog gene promoter might be a cell cycle-independent
mechanism of this.(67) While an early published report denied
the contribution of pRB depletion to iPS cell induction, one of
the later studies has demonstrated caspase 3- and 8-mediated
pRB cleavage/inactivation facilitates iPS cell induction.(14,66)
Since pRB is considered to be one of the acute targets of some
of the pluripotent core factors, knockdown of RB might not
show any more additive effect over acute gain of function of
these factors.(65) The ES cells lacking KDM5A fail prema-
turely to maintain Oct4 or Nanog expression under differentia-
tion-promoting conditions.(68) KDM5A might also mediate the
ability of pRB to control mitochondrial biogenesis or func-
tions.(49) Compared with somatic cells, ES and iPS cells con-
tain fewer numbers of mitochondria; cells with far fewer
numbers of organelle maintained high pluripotency but had
lower teratoma-forming activity (which might be relevant to
cell proliferation). In contrast, cells with a comparatively high
number of mitochondria lose pluripotency but gain higher pro-
liferation activity.(69) It would be intriguing to address whether
the status of pRB affects mitochondria biogenesis and pluripo-
tency in ES cells or in cancer stem cells.
Cancer stem cells. Previous studies have detected similarities
between poorly differentiated cancer cells and ES cells.(70)
Core pluripotent genes, polycomb genes and Myc target genes
might play pivotal roles in these shared features.(71) The simul-
taneous disruption of pRb function and contact inhibition of
cells allowed mouse fibroblasts to form a 3D aggregate
expressing a variety of core pluripotent genes, and cells
derived from such aggregate were also shown to form tera-
toma-like tumors in immunodeficient mice.(72) We developed a
similar experimental model, and subsequently identified addi-
tional genetic changes that are in fact required for cancer stem
cell-like behaviors in Rb-deficient cells (Shunsuke Kitajima,
unpublished data, 2011). Detection of core pluripotent gene
transcripts in cancers is often quoted to be circumstantial evi-
dence of ‘cancer stemness’; however, its significance is totally
unclear. Overexpression of Nanog transforms NIH3T3 fibro-
blasts and induces cancer stem-like cells from astrocytes.(73,74)
Sox2 (as an esophageal ‘oncogene’) and Nanog have been
implicated in the anchorage-independent growth of tumor
cells.(75,76) Indeed, phenomenally, anchorage-independent
growth is hard to distinguish from sphere formation or cancer
transplantability to immunodeficient mice. However, it is also
possible that such circumstantial evidence is non-specifically
associated with a genome-wide change in chromatin structure
in transformed cells. Attenuation of Rb-deficient pituitary can-
cers by deletion of the KDM5A loci implies Rb-deficient carci-
nogenesis might depend on chromatin remodeling.(68)
Epigenetic mechanisms are known to affect the causality of
human retinoblastoma progression.(55) We observed pRb coop-
erates with a histone methyltransferase Suv39h1 in suppressing
carcinogenesis.(10) pRB inactivation induces cell cycle reentry
or tumorigenicity in postmitotic fully differentiated cells while
preserving or even reviving their differentiation potential.(77–80)
Based on these observations, we might be able to establish
new in vivo and in vitro models to address the exact role of
pRB in stem cell-like behaviors seen in cancer cells.
Conclusion
To achieve a greater understanding of the roles of pRB during
tumor progression, future research should focus on the gen-
ome-wide impact of pRB inactivation, which could be medi-
ated by altered cell signaling, cellular metabolism and
chromatin remodeling.
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